Sorafenib, an FLT3 inhibitor employed in AML, produces the inhibition of ABC pumps, avoiding the efflux of cytarabine by MRP7 and MRP8 pumps and thereby increasing the cytarabine-sensitivity of blast cells [89,90]. This evidence concerns the gene ABCC10 and acute myeloid leukemia.